Reviews/Polyphenols and Antioxidants/Gut microbiota metabolise polyphenols
Bio · POLY-BIO-01 · v2
Across seven human trials, researchers fed people different plant polyphenols and then measured new compounds in their urine or blood that the body itself cannot make, showing that gut bacteria had broken the polyphenols down into those products. This happened with several unrelated polyphenol types: pomegranate and oak ellagitannins turned into urolithins [1][5][11], a polyphenol supplement raised urolithin A alongside the bacteria that produce it [2], cranberry polyphenols produced phenolic-acid metabolites [3], and a mixed extract produced equol and urolithins [4][9]. Two trials go beyond simple association: one raised the share of people able to make the conversion [2], and one turned non-producers into producers after exposure [5]. The panel treated this as a basic, repeatedly confirmed phenomenon, with the main caveats being that not everyone's microbiota performs the conversion and that calling the products 'bioactive' leans on secondary health signals. The conversion itself is well shown; the 'bioactive' part is less firmly carried.
Independent human RCTs demonstrate gut-microbial conversion of dietary polyphenols into measurable downstream metabolites across multiple polyphenol classes: ellagitannins into urolithins [1][5][11], a polyphenol-based prebiotic into urolithin A with identified producer taxa such as Gordonibacter [2], cranberry polyphenols into catechol-O-sulfate and 4-hydroxyhippuric acid [3], and a mixed resveratrol, pomegranate and isoflavone extract into urolithin, equol and lunularin metabotypes [4][9]. Causal support is stronger than correlation in two trials: in [2] the proportion capable of converting polyphenols into urolithin A rose to 100% versus 44.4%, and in [5] three of the non-producers became producers after pomegranate extract. Products carry associated health signals, including cardiovascular biomarker changes [5], improved intestinal permeability [9], and lower post-surgical pain scores [11]. The contested point: The division is over strength of causal attribution and over the word 'bioactive'. Most papers detect metabolites after intake and correlate producer taxa rather than directly manipulating the microbiota, so the mechanism is largely inferred per-paper; and the health effects that justify 'bioactive' are downstream, variable secondary endpoints rather than the core conversion.
All 14 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Polyphenols and Antioxidants, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Much human evidence is associative — metabolites are detected after intake and producer taxa correlate, but per-paper causal attribution to microbiota is often inferential rather than directly manipulated.
Large interindividual variability: UM0 non-producers exist [5][9], so polyphenol metabolism is not universal; the claim holds as 'microbiota can metabolise' rather than 'all individuals metabolise'.
Where it remains uncertain. Conversion is not universal — urolithin metabotype 0 non-producers exist [5][9] — and the 'bioactive' label rests on secondary health signals rather than the conversion itself.
Aleatory
Metabotype is an individual trait: UM0 non-producers exist [5][9] and conversion capacity differs across people [2], so outcomes vary person to person.
Epistemic
Candidate producers are named (Gordonibacter [2], Eggerthella [3]) but the full set of species and pathways performing each conversion is not established in the corpus.
Inferential
No included trial isolates microbiota via germ-free or antibiotic controls; conversion is attributed to microbiota from metabolite appearance and taxon correlation, with [2] and [5] the nearest to direct manipulation.
The load-bearing papers from a corpus of 14, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Human RCT establishing microbial conversion of ellagitannins into urolithins with health relevance
“Ellagitannins, and their hydrolyzed product ellagic acid, interact with the gut microbiota to yield secondary metabolites known as urolithins that may have health benefits.”
Panel auditInternal validity: medium · scope of inference: Healthy adults taking a standardized pomegranate (ellagitannin) extract for 4 weeks.Key limitations: urolithin increase not significant · small/unspecified n · short duration
Near-interventional evidence that the microbiota drive polyphenol-to-urolithin conversion
“A higher proportion of synbiotic participants were capable of converting polyphenols into UroA (Day 91, 100% vs. 44.4%; p < 0.01).”
Panel auditInternal validity: medium · scope of inference: Healthy adults given a 24-strain probiotic plus pomegranate polyphenol prebiotic over 91 days.Key limitations: small n · added strains confound native-microbiota attribution · healthy population only
Extends the claim to cranberry polyphenols and explicitly labels the microbial products bioactive
“Cranberry polyphenols reach the colon largely unmetabolized, where they interact with the gut microbiota to generate bioactive metabolites.”
Panel auditInternal validity: medium · scope of inference: Overweight/obese adults given low-dose cranberry polyphenols for 6 weeks.Key limitations: correlative microbe-metabolite link · pilot sample · mixed host/microbial metabolites
3 of 14 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
A fundamental mechanistic claim replicated across independent polyphenol classes and multiple human RCTs, with only interindividual variability and the softness of 'bioactive' as minor caveats.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No microbiota-isolating control. Without germ-free or antibiotic arms, the corpus infers rather than demonstrates that microbiota are necessary for conversion. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: RCTs or ex vivo fecal-fermentation studies with antibiotic suppression or germ-free comparators to establish microbiota as the required agent.
Open question: Is gut microbiota strictly necessary for polyphenol-to-metabolite conversion in humans? Why it is still open: No included trial uses germ-free or antibiotic controls to remove the microbiota and test whether conversion ceases.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19